Catalog No.
Product Name
Application
Product Information
Citations
-
Hsp110-STAT3 Interaction Inhibitor
Hsp110-STAT3 PPI-IN-1 is a potent inhibitor of the Hsp110-STAT3 protein-protein interaction. This compound exhibits antiproliferative activity against the HPAEC cell line, demonstrating an IC50 value of 22.67 μM. It serves as a valuable tool for investigating the role of Hsp110-STAT3 interactions in various biological processes and therapeutic applications. -
STAT3 Inhibitor
S3I-1757 is a selective STAT3 inhibitor that effectively hinders the phosphorylation and dimerization of STAT3 proteins. By targeting this pathway, S3I-1757 demonstrates significant potential in the study of STAT3-driven malignancies, including melanoma. Its application is particularly relevant for investigating therapeutic strategies in cancers characterized by aberrant STAT3 activation. -
STAT3 Inhibitor
Ac-GpYLPQTV-NH2 is a selective inhibitor of the STAT3 signaling pathway, exhibiting an IC50 value of 0.33 μM. This compound demonstrates significant antitumor activity, making it a valuable tool for research in cancer biology and therapeutic applications targeting STAT3-mediated oncogenic functions. Its efficacy in modulating STAT3 activity provides insights into the role of this transcription factor in tumor progression and treatment resistance. -
STAT5a Inhibitor
Stafia-1-dipivaloyloxymethyl ester functions as a selective inhibitor of STAT5a. This compound effectively reduces the expression of phosphorylated STAT5a (pSTAT5a) in a concentration-dependent manner, demonstrating significant inhibition at doses ranging from 0-200 μM, while exhibiting minimal impact on phosphorylated STAT5b (pSTAT5b). Stafia-1-dipivaloyloxymethyl ester is valuable for research applications targeting STAT signaling pathways. -
STAT Inhibitor
Eupalinolide K is a selective STAT3 inhibitor derived from Eupatorium lindleyanum. This sesquiterpene lactone functions as a Michael reaction acceptor, demonstrating significant potential in modulating STAT3 signaling pathways. Its inhibitory activity makes Eupalinolide K useful in research related to cancer biology and inflammatory responses, providing insights into therapeutic strategies targeting the STAT3 pathway. -
STAT6 PROTAC Degrader
PROTAC STAT6 degrader-3 is a highly potent degrader targeting STAT6, exhibiting a DC50 of less than 1 nM. This compound facilitates the targeted degradation of STAT6, making it a valuable tool for investigating allergic and inflammatory diseases as well as various cancers. Its application in research can provide insights into the role of STAT6 in disease pathways and therapeutic interventions. -
STAT3 Degrader
KT-333 ammonium is a selective STAT3 degrader that initiates the proteolytic degradation of the STAT3 protein via the ubiquitin-proteasome pathway. By binding to both STAT3 and the E3 ubiquitin ligase von Hippel-Lindau (VHL), KT-333 ammonium effectively targets and eliminates STAT3, exhibiting significant antitumor activity. This compound is particularly useful in the study of hematologic malignancies, including large granular lymphocytic leukemia (LGL-L), peripheral T-cell lymphoma (PTCL), and cutaneous T-cell lymphoma (CTCL). -
STAT3 Inhibitor
STAT3-IN-7 is a potent inhibitor targeting Signal Transducer and Activator of Transcription 3 (STAT3). This aryl sulfonamido azetidine compound demonstrates significant anticancer properties, making it a valuable tool for research in cancer biology. It offers applications in studies aimed at elucidating the role of STAT3 signaling in tumor progression and therapeutic resistance. -
STAT3 Inhibitor
STAT3-IN-8 (compound H172) is a selective inhibitor of Signal Transducer and Activator of Transcription 3 (STAT3). It exhibits potent inhibitory activity against STAT3 signaling, which is often dysregulated in various cancers. This compound is valuable for cancer research, particularly in studies exploring the role of STAT3 in tumorigenesis and therapeutic interventions. -
STAT3 Degrader
KT-333 diammonium is a selective STAT3 degrader that utilizes the ubiquitin-proteasome system to target and degrade STAT3 protein. By binding to both STAT3 and the E3 ubiquitin ligase von Hippel-Lindau protein (VHL), it mediates the selective reduction of STAT3 levels, exhibiting significant antitumor activity. KT-333 diammonium is valuable in researching hematologic malignancies, including large granular lymphocytic leukemia (LGL-L), peripheral T-cell lymphoma (PTCL), and cutaneous T-cell lymphoma (CTCL). -
STAT3 Inhibitor
HJC0149 is a selective inhibitor of signal transducer and activator of transcription 3 (STAT3), functioning by disrupting STAT3 signaling pathways. This compound exhibits potent biological activity, making it a valuable tool for research focused on cancer and inflammatory diseases where STAT3 plays a critical role in regulating cell proliferation and survival. Its efficacy positions HJC0149 as an essential reagent for investigating the therapeutic potential of STAT3 modulation in preclinical studies. -
STAT3 HiBiT Degrader
STAT3 HiBiT Degrader 1 is a potent compound that selectively targets the signal transducer and activator of transcription 3 (STAT3) for degradation. It demonstrates a DC50 value of less than 0.05 μM in A549 cells, highlighting its efficacy in reducing STAT3 levels. This degrader offers valuable tools for studying the role of STAT3 in cancer and other diseases, facilitating the investigation of pathways regulated by this transcription factor. -
STAT3 Inhibitor
STAT3-IN-29 is a selective inhibitor of Signal Transducer and Activator of Transcription 3 (STAT3). It demonstrates potent anti-proliferative effects on HaCaT cells with an IC50 value of 0.09 µM and has been shown to alleviate IMQ-induced psoriasis in mouse models. This compound is valuable for research aimed at understanding STAT3 signaling pathways and developing therapeutic strategies for psoriasis and other STAT3-related conditions. -
STAT3 Inhibitor
STAT3-IN-36 is a potent inhibitor of STAT3, with additional activity against LRPPRC and CDK1. This compound demonstrates significant anticancer effects, evidenced by its ability to inhibit HGC27 cells with an IC50 of 1.8 μM. STAT3-IN-36 serves as a valuable tool for research applications focused on cancer biology, particularly in elucidating the mechanistic roles of STAT3 and its associated pathways in tumor progression. -
STAT6 Modulator
STAT6 modulator-3 is an inhibitor of the STAT6 signaling pathway, exhibiting an IC50 value of less than 300 nM. This compound demonstrates significant biological activity in modulating immune responses and inflammatory processes, making it a valuable tool for cancer research and inflammation studies. Its ability to selectively target STAT6 allows for in-depth investigations into the role of this transcription factor in various disease states. -
STAT6 Inhibitor
STAT6-IN-11 is a selective inhibitor of the transcription factor STAT6, exhibiting an EC50 of 6 nM. It effectively reduces CCL17 secretion in peripheral human whole blood stimulated via the IL-13-IL-13 receptor/IL-4 receptor pathway, with an IC50 of 83 nM. This compound is valuable for research into dermatological and respiratory conditions, providing insights into the role of STAT6 in immune response and inflammation. -
STAT3 Inhibitor
Crispene E is a selective STAT3 inhibitor that effectively disrupts STAT3 dimerization with an IC50 of 10.27 μM. This compound demonstrates specific cytotoxicity towards STAT3-dependent MDA-MB-231 breast cancer cells, making it a valuable tool for studies investigating breast cancer pathways and potential therapeutic targets. Research applications include exploring the role of STAT3 in tumorigenesis and evaluating the efficacy of STAT3 inhibition in cancer treatment strategies. -
STAT3 Inhibitor
STAT3-IN-35 is a selective inhibitor of Signal Transducer and Activator of Transcription 3 (STAT3) that targets the SH2 domain. This compound effectively inhibits STAT3 phosphorylation, demonstrating significant antiproliferative effects in triple-negative breast cancer (TNBC) cell lines. Additionally, STAT3-IN-35 exhibits pronounced antitumor activity and toxicity in TNBC xenograft models, making it a valuable tool for cancer research and therapeutic development. -
STAT3 PROTAC Degrader
SD-2301 is a selective STAT3 PROTAC degrader that targets and induces the degradation of STAT3 while preserving the expression of other STAT family members such as STAT1, STAT2, STAT4, STAT5, and STAT6. It has demonstrated anti-tumor efficacy in B16F10-bearing mouse models, making it a valuable tool for cancer research. This compound can be utilized in studies focused on the modulation of STAT3 pathways and the development of targeted therapies. -
STAT3 Inhibitor
STAT3-IN-47 is a potent oral inhibitor of the Signal Transducer and Activator of Transcription 3 (STAT3) pathway. This compound demonstrates significant anti-tumor activity across various cancer cell lines, including HeLa, HepG2, U87, and LN229. By effectively suppressing STAT3 activation in vitro, STAT3-IN-47 serves as a valuable tool for research on solid tumors, with particular relevance to central nervous system malignancies and hepatocellular carcinoma. -
STAT6 Inhibitor
STAT6-IN-8 is a selective inhibitor of the signal transducer and activator of transcription 6 (STAT6), known for its potential anti-inflammatory and anti-allergic properties. This compound serves as a valuable tool for investigating STAT6-associated pathologies, including various inflammatory conditions such as atopic dermatitis and bronchial asthma, as well as allergic diseases like allergic rhinitis and chronic sinusitis. Its applications in research can contribute to a better understanding of these conditions and aid in the development of targeted therapies. -
STAT6 Molecular Glue
STAT6 degrader-1 is a bifunctional molecular glue that specifically targets STAT6 by recruiting E3 ubiquitin ligase, leading to the proteasomal degradation of the protein. This degradation mechanism allows for the modulation of STAT6 activity, making it a valuable tool in the study of cancer biology, inflammatory diseases, and colorectal cancer. Researchers can utilize STAT6 degrader-1 to explore therapeutic strategies aimed at disrupting STAT6 signaling pathways. -
pSTAT3 Inhibitor
(E/Z)-OSM-SMI-10B is a potent inhibitor of phosphorylated STAT3 (pSTAT3). This compound effectively decreases OSM-induced STAT3 phosphorylation in cancer cells when co-incubated with Oncostatin M (OSM). Its ability to modulate STAT3 signaling makes (E/Z)-OSM-SMI-10B a valuable tool for research in cancer biology and therapeutic development. -
STAT3 Inhibitor
STAT3-IN-23 is a potent inhibitor of signal transducer and activator of transcription 3 (STAT3). By selectively targeting STAT3, this compound disrupts its signaling pathway, leading to decreased tumor cell proliferation and enhanced apoptosis. STAT3-IN-23 is valuable for research applications focused on cancer biology, inflammation, and the understanding of STAT3-mediated signaling in various pathological conditions. -
PROTAC STAT6 Degrader
PROTAC STAT6 Degrader-2 is a potent bifunctional degrader that specifically targets signal transducer and activator of transcription 6 (STAT6). It demonstrates high efficiency with a DC50 of 1-10 nM in human peripheral blood mononuclear cells (PBMC) and less than 100 nM in HEK293-HIBiT-STAT6 cells. This compound is ideal for research applications related to STAT6-mediated diseases, facilitating the study of its role in various biological processes. -
STAT6 Ligand Active Control
AK-068-OH is a STAT6 ligand active control designed for use in PROTAC applications. This compound plays a crucial role in modulating STAT6 activity, enabling researchers to investigate its biological functions and pathways. Its application is particularly relevant in studies focusing on immune response and signaling mechanisms associated with various diseases. -
STAT3 Inhibitor
STAT3-IN-5 is a potent inhibitor of the signal transducer and activator of transcription 3 (STAT3), primarily targeting the phosphorylation of STAT3 at the Y705 residue with an EC50 of 170 nM. This compound effectively blocks cytokine-induced JAK activation and induces apoptosis in cancer cells. STAT3-IN-5 is valuable for research focused on cancer biology and the therapeutic modulation of the STAT3 signaling pathway. -
STAT3 Dual Phosphorylation Inhibitor
STAT3-IN-32 is a potent inhibitor of dual phosphorylation of STAT3, targeting the SH2 domain with a dissociation constant (KD) of 21.3 nM. It effectively inhibits STAT3 phosphorylation at tyrosine 705 and serine 727, leading to the disruption of nuclear transcription and mitochondrial oxidative phosphorylation functions. In cellular assays, STAT3-IN-32 demonstrates an IC50 of 5.3 nM for STAT3 luciferase activity in HEK293T cells and 4.2 nM for ATP production inhibition in BxPC-3 cells. Additionally, STAT3-IN-32 exhibits significant anti-tumor effects in pancreatic cancer xenograft models, making it a valuable compound for cancer research. -
STAT3 Inhibitor
WZ-2-033 is a selective inhibitor of Signal Transducer and Activator of Transcription 3 (STAT3). This compound effectively reduces the proliferation, colony survival, migration, and invasion of cancer cell lines MDA-MB-231, HCC70, and MDA-MB231-4175, with IC50 values of 0.7 μM, 1.3 μM, and 1.3 μM, respectively. Its ability to modulate STAT3 signaling makes WZ-2-033 a valuable tool in cancer research and therapeutic development targeting STAT3-mediated pathways. -
STAT3 Inhibitor
STAT3-IN-43 is a covalent inhibitor that targets the allosteric site at the intersection of the STAT3 coiled-coil domain and DNA-binding domain, demonstrating an IC50 of 40.7 μM. This compound effectively modulates STAT3 activity, making it a valuable tool in cancer research to study the role of STAT3 in tumorigenesis and therapeutic resistance. Its application may extend to elucidating the molecular mechanisms of STAT3-mediated signaling pathways. -
PROTAC STAT3 Degrader
SD-91 is a selective PROTAC-based degrader targeting STAT3 with a Ki of 5.5 nM, demonstrating over 300-fold selectivity against other STAT family proteins. This compound effectively induces the degradation of STAT3 protein in cellular systems. It shows potential anticancer activity, particularly in myeloid leukemia and lymphoma research applications. -
STAT3 Degrader
PROTAC STAT3 degrader-2 is a highly selective degrader targeting the STAT3 protein with a DC50 value of 3.54 μM in Molm-16 cells. This compound is designed for cancer research applications, facilitating the targeted degradation of STAT3 to investigate its role in tumorigenesis. Additionally, PROTAC STAT3 degrader-2 features an alkyne group that enables copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing molecules, providing versatility in experimental designs. -
PROTAC STAT3 Degrader
S3D5 is a selective PROTAC degrader specifically targeting STAT3, with a dissociation constant (KD) of 4.35 μM. It effectively induces degradation of the STAT3 protein in HepG2 cells, demonstrating minimal impact on other STAT proteins. This degradation is mediated via the ubiquitin-proteasome system, contributing to its potent anti-proliferative effects in hepatocellular carcinoma by activating the p53 pathway. S3D5 serves as a valuable tool for research focused on the mechanisms underlying hepatocellular carcinoma. -
STAT3 Inhibitor
STAT3-IN-4 is a selective inhibitor of the Signal Transducer and Activator of Transcription 3 (STAT3) signaling pathway. With dissociation constants (Kd) of 22.75 μM for the mutant STAT3 (I634S/Q635G) and 4.59 μM for the wild-type, this compound demonstrates significant potential in attenuating STAT3 activity. STAT3-IN-4 has been shown to inhibit the proliferation of tumor cells, making it a valuable tool for cancer research and therapeutic studies targeting aberrant STAT3 signaling in various malignancies. -
STAT3 Inhibitor
STAT3-IN-33 is a selective STAT3 inhibitor that demonstrates significant anti-cancer properties. It effectively inhibits cell proliferation in HCT116, MCF-7, and MDA-MB-231 cancer cell lines, with IC50 values of 6.44, 3.29, and 4.86 μM, respectively. This compound is valuable for research focused on the therapeutic applications of STAT3 inhibition in breast and colon cancer. -
STAT3 Degrader
STAT3 Degrader-1 is a potent STAT3 degrader that targets and promotes the degradation of the STAT3 protein. This compound facilitates investigations into its role in cancer biology and therapeutic strategies by effectively reducing STAT3 levels. Additionally, STAT3 Degrader-1 features an alkyne group and is capable of undergoing copper-catalyzed azide-alkyne cycloaddition (CuAAc), enabling versatile applications in click chemistry for further research opportunities. -
STAT3 Inhibitor
STAT3-IN-30 is a selective inhibitor of Signal Transducer and Activator of Transcription 3 (STAT3) with an EC50 of 13.8 μM. This compound effectively impairs STAT3-mediated signaling pathways, thereby influencing cell proliferation and survival. STAT3-IN-30 is suitable for research applications focused on cancer biology, immune response, and chronic inflammatory disorders, providing valuable insights into therapeutic targets involving STAT3 dysregulation. -
STAT3 Inhibitor
inS3-54-A26 is a selective inhibitor of the Signal Transducer and Activator of Transcription 3 (STAT3) pathway. It exhibits cytotoxicity in non-cancerous lung fibroblasts with an IC50 of 4.0 μM. This compound is valuable for research applications in cancer biology and therapeutic development, particularly for exploring STAT3's role in oncogenesis and its potential as a target for anti-cancer strategies. -
Stat3 Negative Control
STAT3-IN-21 is a cell-permeable peptide designed as a negative control for the assessment of STAT3 activity. It serves as a crucial tool for differentiating specific STAT3-mediated effects from non-specific interactions in experimental settings. This reagent is ideal for research applications focused on understanding the role of STAT3 in signaling pathways and cellular processes. -
STAT3 Inhibitor
STAT3-IN-15 is a selective inhibitor of STAT3, a transcription factor implicated in various pathological conditions, including idiopathic pulmonary fibrosis (IPF). This compound effectively inhibits STAT3 phosphorylation, leading to a reduction in migration and deformation of epithelial cells stimulated by TGF-β1. Additionally, STAT3-IN-15 demonstrates the ability to hinder epithelial-mesenchymal transition (EMT), making it a valuable tool for research in fibrosis and related cellular processes. -
STAT3 Inhibitor
Pulchinenoside E2 is a triterpene saponin that functions as a STAT3 inhibitor. It exhibits dual activity by inhibiting STAT3 and autophagy, demonstrating cytotoxic effects on HL-60 cells with an IC50 value of 2.6 µg/mL. This compound is valuable for research applications focused on cancer biology and the modulation of signaling pathways involved in cell proliferation and survival. -
STAT Phosphorylation Inhibitor
XZH-5 is a STAT phosphorylation inhibitor that specifically targets the phosphorylation of STAT3. This compound induces apoptosis in various cancer cell lines and significantly reduces their colony-forming ability. It serves as a valuable tool for researchers investigating the role of STAT3 in tumorigenesis and potential therapeutic strategies for cancer treatment. -
STAT3 Inhibitor
PMMB-187 is a selective inhibitor of the Signal Transducer and Activator of Transcription 3 (STAT3), showing an IC50 value of 1.81 μM in MDA-MB-231 breast cancer cells. This compound effectively induces apoptosis by disrupting STAT3's transcriptional activity and nuclear localization, leading to a decrease in downstream gene expression. Additionally, PMMB-187 diminishes mitochondrial membrane potential, increases reactive oxygen species (ROS) production, and upregulates apoptosis-related protein levels. Its unique mechanism positions PMMB-187 as a valuable tool in cancer research applications. -
STAT6 Modulator
Medrysone, also known as 6α-Methyl-11β-hydroxyprogesterone, functions as a STAT6 modulator with significant implications for macrophage polarization. This compound enhances IL-4-induced STAT6 activation, leading to increased expression of M2 macrophage markers and elevated secretion of pro-angiogenic factors such as VEGF and CCL2. Additionally, Medrysone promotes the migratory capacity of M2-like macrophages towards endothelial cells, thereby facilitating tissue repair processes. Its efficacy in regulating macrophage polarization makes it a valuable tool for research on corneal injury and wound healing applications. -
EPAC1 Activator, STAT3 Modulator
DM243 is an EPAC1 activator and STAT3 modulator known for its ability to increase GTP-bound Rap1 levels specifically in EPAC1-expressing cells, while exhibiting no effects on EPAC2 or PKA. This compound effectively reduces IL-6/IL-6Rα-induced STAT3 phosphorylation in endothelial cells and suppresses TGF-β1-mediated fibroblast-to-myofibroblast transition, leading to decreased levels of α-smooth muscle actin and Collagen I in lung fibroblasts. Additionally, DM243 demonstrates minimal cytotoxicity in normal human lung fibroblasts, making it a valuable tool for studies related to fibrosis and inflammation. -
JAK/STAT Inhibitor
Phenylpyropene C is a JAK/STAT pathway inhibitor known to effectively inhibit interferon-gamma (IFN-γ) mediated expression of reporter genes, with an IC50 range of 5.4 to 10.8 μM. Additionally, it serves as an inhibitor of acyl-CoA, exhibiting an IC50 of 16.0 μM. This compound is valuable for research applications focusing on the modulation of immune responses and the exploration of cytokine signaling pathways. -
EPAC1 Activator, STAT3 Phosphorylation Inhibitor
DM245 is an EPAC1 activator and STAT3 phosphorylation inhibitor. It effectively increases Rap1-GTP levels through selective activation of EPAC1, without affecting EPAC2 or PKA. DM245 mitigates IL-6/IL-6Rα-mediated STAT3 phosphorylation in endothelial cells and inhibits the TGF-β1-induced transition of fibroblasts to myofibroblasts, leading to decreased levels of αSMA and Collagen I. Importantly, DM245 shows minimal cytotoxicity in normal human lung fibroblasts, indicating a high safety profile for extended exposure. -
STAT3 Ligand
STAT3-IN-26 is a selective ligand for the transcription factor STAT3, a critical regulator of cell growth and survival. This compound is instrumental in the synthesis of PROTACs (Proteolysis-targeting chimeras) aimed at inducing the degradation of STAT3. It is particularly relevant for research into targeted cancer therapies and studies on cellular signaling pathways involving STAT3. -
STAT3 PROTAC Degrader
PROTAC STAT3 degrader-3 (S3D1) targets the STAT3 protein through a PROTAC-mediated degradation mechanism. This compound exhibits potent anticancer activity by facilitating the ubiquitination and subsequent proteasomal degradation of STAT3, a key oncogenic transcription factor. It is primarily applied in research focused on cancer biology, particularly in studies investigating the therapeutic potential of targeting the STAT3 signaling pathway. -
AKT1/SRC/STAT3/EGFR Binder
(+)−Theta-cypermethrin is a stereoisomer of cypermethrin that functions as a selective binder to AKT1, SRC, STAT3, and epidermal growth factor receptor (EGFR). This compound is known to penetrate the blood-brain barrier, leading to alterations in the amplitude of delayed rectifier potassium channel currents and significant shifts in the activation and inactivation curves at elevated concentrations. Additionally, (+)-Theta-cypermethrin induces abnormal electrical activity in rat hippocampal neurons and is associated with chronic respiratory system damage and neurotoxicity. It serves as a valuable tool for research into signal transduction pathways and neuropharmacology.
